Our mission at LungLife is driven from important and compelling statistical data about lung cancer. According to the American Society of Clinical Oncology, more than 2.2 million new people were diagnosed with lung cancer in 2020. That’s one new lung cancer diagnosis every 14 seconds worldwide. Every 14 seconds, someone’s life is turned upside down, and family and friends are involuntarily moved into a challenging support role.
To further complicate matters, a study published by the National Institute of Health reports that the great majority of lung cancer cases are already in advanced stages before doctors diagnose them. The prognosis for late-stage lung cancer is poor. Just 7% of patients diagnosed with metastasized non-small cell lung cancer survive past five years.
While new treatments are attempting to improve advanced lung cancer prognoses, the key to increasing the overall survival rate is early detection. When detected early, the expected outcomes for lung cancer patients improve greatly. When the same non-small cell lung cancer is detected in stage one, the five-year survival rate is 63%. Early detection correlates with higher survival rates.
Here’s where we have some exciting news to share. Our company is using artificial intelligence to aid with the early detection of lung cancer. LungLife has developed technology that pairs a simple blood draw with artificial intelligence to provide clinicians and patients the information they need to make informed decisions about the management of lung nodules and lung cancer. Early detection means better care, better outcomes, and longer lives.
Imagine a world where 14 seconds come and go without lives being thrown into turmoil.
We at LungLife strive to be a driving force in the early detection of lung cancer.
For more information about the great work we are doing, visit our website at lunglife.ai.com.